title: Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia.
authors.affiliation: a Department of Oncology-Hematology, Hematology Unit , Fondazione IRCCS Policlinico San Matteo , Pavia , Italy.
authors.forename: Ester Maria
authors.initials: EM
authors.lastname: Orlandi
authors.affiliation: a Department of Oncology-Hematology, Hematology Unit , Fondazione IRCCS Policlinico San Matteo , Pavia , Italy.|b Department of Molecular Medicine , University of Pavia , Pavia , Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Elena
authors.affiliation: c Department of Oncology-Hematology , School of Hematology, University of Pavia, Hematology Unit, Fondazione IRCCS Policlinico San Matteo , Pavia , Italy.
authors.forename: Elisa
authors.initials: E
authors.lastname: Bono
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006509:Hepatitis B / Q000150:complications* / Q000175:diagnosis / Q000276:immunology / Q000821:virology*; D006515:Hepatitis B virus / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D014775:Virus Activation / Q000187:drug effects* / Q000276:immunology; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors